VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.
Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, Bertelli G, Chang CW, Desai R, Gupta K, Wilson TR, Flechais A, Bardia A.
Lindeman GJ, et al. Among authors: jerzak kj.
Clin Cancer Res. 2022 Aug 2;28(15):3256-3267. doi: 10.1158/1078-0432.CCR-21-3811.
Clin Cancer Res. 2022.
PMID: 35583555
Free PMC article.
Clinical Trial.